Evidence map›Paper›PMID 42746222›Full record

ReviewFrontiers in cell and developmental biology2026

Target, silence, replace: a review on RNA-based drugs in modern medicine.

Poonam Mundlia, Suraj Pratap Singh, Pritiman Pothal, Tanya Thakur, Reema Kathuria, Sudhanshu Maurya, Akanksha Sharma, Honey Goel, Ankur Pandey, Pavitra Ranawat and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Poonam Mundlia *Department of Biophysics, Panjab University, Chandigarh, India.
Suraj Pratap Singh *Department of Biophysics, Panjab University, Chandigarh, India.
Pritiman Pothal *University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Tanya Thakur *Department of Biophysics, Panjab University, Chandigarh, India.
Reema KathuriaDepartment of Biophysics, Panjab University, Chandigarh, India.
Sudhanshu MauryaDepartment of Biotechnology, Panjab University, Chandigarh, India.
Akanksha SharmaDepartment of Biophysics, Panjab University, Chandigarh, India.
Honey GoelDepartment of Pharmaceutics, University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot, India.
Ankur PandeyDepartment of Chemistry, Panjab University, Chandigarh, India.
Pavitra RanawatDepartment of Biophysics, Panjab University, Chandigarh, India.
Gurpal SinghUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Ravi Pratap BarnwalDepartment of Biophysics, Panjab University, Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA therapies have evolved into a revolutionary approach in contemporary medicine for treating various diseases by directly targeting RNA molecules engaged in disease pathogenesis. These therapeutic agents regulate biological processes through diverse mechanisms, including modulation of RNA function and gene expression. Medical applications of RNA are greatly enhanced by its structure, adaptability, and capacity for targeted binding. Among these traits is its ability to bind to certain molecules unique to those chemicals. RNA-based treatments have emerged from advancements in the production, modification, and cellular transport of RNA molecules. Several RNA drugs have been approved whereas some are under trial for few diseases. RNA therapeutics can function at the level of RNAs, DNAs and proteins. The evolution of mRNA vaccines during the COVID-19 epidemic emphasizes the exciting potential of RNA therapies in the treatment of diseases. This article provides a comprehensive overview of the several forms of RNA therapies, including small-interfering RNA (siRNA), messenger RNA (mRNA), and antisense-oligonucleotides (ASOs), together with information on their action mechanisms and delivery strategies that improve cellular absorption and shield RNA molecules from degradation. Further, CRISPR-based editing of the genome can be employed for modification of target RNA sequences for various disorders. Development of RNA aptamers have also been identified as pivotal RNA-therapeutic candidate. Additionally, we have explained mechanistic details and examples of drugs approved for RNA therapy. Emphasizing their potential to enhance patient outcomes and fulfil unmet medical requirements, we also highlight the clinical development of RNA therapies in treating cancer and other infectious diseases.

Indexed as

antisense oligonucleotidesaptamermessenger RNAnanoparticle deliveryRNA interferenceRNA therapeutics

Identifiers

PMID42746222
PMCPMC13575629

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.